A phase I trial demonstrated that monthly docetaxel (Taxotere) and weekly gemcitabine (Gemzar) had both acceptable toxicity and encouraging antineoplastic activity in patients with previously treated advanced breast cancer. This phase II trial will determine the efficacy and toxicity of this regimen in advanced breast cancer patients who have measurable disease refractory to, or relapsed after, first-line or adjuvant chemotherapy.
Epirubicin (Ellence) is currently being studied in combination with the taxanes, such as docetaxel (Taxotere), in patients with advanced breast cancer. As a single agent, docetaxel has proven to be a very active drug in breast cancer, so the results of these combination trials are awaited with interest. Our experience has shown epirubicin/docetaxel to be a feasible and active combination in breast cancer.
The most efficacious primary chemotherapy regimens used to treat breast cancer contain anthracyclines. Unfortunately, a significant proportion of breast cancers fail to respond to such therapy. Therefore the aims of this study were (1) to determine the efficacy of primary docetaxel (Taxotere) in patients that initially fail to respond to anthracycline-based primary chemotherapy, and (2) to compare the efficacy of docetaxel with anthracycline-based primary chemotherapy in patients that are initially responsive to such therapy.
The degree of pathologic response of tumor to primary chemotherapy is of considerable prognostic importance in patients with breast cancer. The addition of docetaxel (Taxotere) to an anthracycline-based primary chemotherapy regimen has been shown to result in significantly improved pathologic breast cancer response. The identification of predictors of treatment response will permit cytotoxic regimens to be tailored to individual patient requirements and permit pathologic response rates to be improved.
The aim of this study was to assess the efficacy and toxicity of the combination of docetaxel (Taxotere) and vinorelbine (Navelbine), every 15 days, in anthracycline-pretreated metastatic breast cancer patients.
Between June 1996 and March 1998, 429 first-line metastatic breast cancer patients were randomized to receive AT (doxorubicin [Adriamycin] 50 mg/m² and docetaxel [Taxotere] 75 mg/m²) or AC (doxorubicin 60 mg/m² and cyclophosphamide [Cytoxan, Neosar] 600 mg/m²), day 1 every 3 weeks for a maximum of eight cycles.
The combination of docetaxel (Taxotere) and doxorubicin is highly effective in breast cancer, but it presents relatively high hematologic toxicity. Recent data have suggested advantages for the weekly administration of docetaxel regarding the safety
The objective of this study was to assess the response rate and the toxicity of the combination docetaxel (Taxotere)/vinorelbine (Navelbine) in patients with advanced breast cancer.
Docetaxel (Taxotere) and vinorelbine (Navelbine) are active agents in the treatment of metastatic breast cancer. Preclinical data suggest that there may be synergism between vinca alkaloids and taxane compounds. The current study evaluates the combination of docetaxel and vinorelbine with concurrent granulocyte colony-stimulating factor (G-CSF, filgrastim [Neupogen]) in anthracycline-refractory breast cancer. The objectives of this study are to determine the response rate, time to progression, survival, and toxicities of this regimen.
Weekly administration of taxanes as palliative treatment in metastatic breast cancer has been reported with significantly reduced hematologic toxicity and comparable efficacy to standard every-3-week protocols. This study update provides mature results with weekly docetaxel (Taxotere) in a larger patient population.
Increasing the dose density of active drugs by delivering maximum tolerated doses sequentially with minimal intervals between cycles could potentially increase response rate and benefit in metastatic breast cancer. We tested this hypothesis by assigning
Based on results from phase I studies, one of the recommended doses for doxorubicin/docetaxel (Taxotere) is doxorubicin 60 mg/m² plus docetaxel 60 mg/m² every 21 days. However, information on the efficacy and toxicity of this dose level in
Docetaxel (Taxotere) is a semisynthetic taxane that has efficacy in combination regimens with doxorubicin (Adriamycin) in the treatment of metastatic breast cancer. This study was instituted to assess the role of this combination in the neoadjuvant treatment of locally advanced breast cancer (LABC).
From March 1996 to March 1998, 106 patients with untreated metastatic breast cancer (MBC) were treated with docetaxel (Taxotere) (100 mg/m²) and doxorubicin (75 mg/m²) on an alternating cycle-by-cycle (doxorubicin, docetaxel, doxorubicin, etc) or sequential (four cycles of docetaxel, then four cycles of doxorubicin) basis, every 3 weeks, for a maximum of eight cycles.
Results of the GEPARDO Trial: A Phase IIB Study Comparing the Combination of Dose-Intensified Doxorubicin and Docetaxel With or Without Tamoxifen in Patients With Operable Breast Cancer
MIAMI, Florida-Results of a recent study suggest that Herceptin (trastuzumab) may be effective as single-agent therapy in chemotherapy-naïve women with metastatic breast cancer, said lead investigator Charles Vogel, MD, clinical professor of medicine, University of Miami School of Medicine.
PITTSBURGH-Four cycles of doxorubicin (Adriamycin) and cyclophosphamide (AC) over 63 days are as effective as six cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) over 6 months in node-negative, early- stage breast cancer, Bernard Fisher, MD, reported at the ASCO annual meeting.
NEW ORLEANS-In a phase II study, combined treatment with Herceptin (trastuzumab) and vinorelbine (Navelbine) improved response rates and survival in women with HER2-positive metastatic breast cancer.
NEW YORK-“Survival rates could be improved if all women understood the benefits of early detection and could utilize high-quality breast cancer screening services in their communities, regardless of their ability to pay,” said Wanda K. Jones, DrPh, leadoff speaker at the National Alliance of Breast Cancer Organizations’ (NABCO) Celebration 2000 fund-raising luncheon.
This book is the 17th volume in the Basic and Clinical Oncology series edited by Bruce D. Cheson, MD. Like other volumes in this series, Expert Consultations in Breast Cancer follows a unique format and seeks to integrate advances in the basic understanding of breast cancer with promising new therapies and changing health- care economics. The integration of these different perspectives provides both a conceptual and pragmatic framework for clinical decision-making.
The results of a multicenter, phase III metastatic breast cancer study indicates that, in women with previously untreated metastatic breast cancer, sequential chemotherapy induction using doxorubicin and docetaxel (Taxotere) is as effective and
NEW ORLEANS-Epirubicin (Ellence) may be an effective single agent for primary treatment of operable breast cancer, according to results of a cooperative group study from the National Tumor Institute, Milan, Italy, presented at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO).
NEW ORLEANS-A pilot study of ultrasound-guided percutaneous radio-frequency ablation (RFA) in patients with early-stage breast cancer suggests that the technique might someday be an alternative to surgical resection in carefully selected patients.
STUTTGART, Germany-Mitoxantrone (Novantrone) alone gives high-risk metastatic breast cancer patients a better quality of life than a combination of fluorouracil, epirubicin, and cyclophosphamide (FEC), according to results presented at the 36th Annual Meeting of the American Society of Clinical Oncology. Yet the single agent appears to work as well as combination therapy when compared for several endpoints.
NEW YORK-Dramatic advances in the treatment, detection, and prevention of breast cancer are occurring because of research efforts of the past 30 years, experts emphasized at the International Roundtable on Breast Cancer: Today’s Choices, Tomorrow’s Chances for a Cure, sponsored by the American-Italian Cancer Foundation and the Susan G. Komen Breast Cancer Foundation.
